Ligand Pharmaceuticals Quarterly Balance Sheet
NASDAQ: LGNDHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ligand Pharmaceuticals financial position
As of Jun 30, 2026, Ligand Pharmaceuticals reported total assets of $2.19 billion, up 130.4% from a year earlier against total liabilities of $1.22 billion. Shareholders' equity stood at $967.5 million, or 44.3% of assets. The company held $1.01 billion in cash and equivalents against $1.13 billion of debt, a net debt position of $119.9 million.
The current ratio (current assets divided by current liabilities) was 31.18, meaning short-term assets cover obligations due within a year. Debt-to-equity was 1.16.
Summary generated from market data by MetaCap's automated system. Methodology
Ligand Pharmaceuticals balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 1.01B | 115.08M | 174.93M | 139.38M | 67.67M | 47.99M | 72.31M | 63.62M | 18.14M | 50.09M | 22.95M | 19.27M |
| Short-Term Investments | 351.06M | 664.33M | 558.59M | 525.15M | 177.35M | 160.91M | 183.86M | 156.02M | 208.79M | 260.50M | 147.35M | 171.23M |
| Receivables | 67.01M | 53.38M | 59.60M | 57.56M | 41.29M | 38.49M | 38.38M | 34.32M | 37.48M | 28.43M | 32.92M | 36.00M |
| Inventory | 10.26M | 13.27M | 9.13M | 11.90M | 15.49M | 14.61M | 14.11M | 16.74M | 18.67M | 21.34M | 23.97M | 25.39M |
| Total Current Assets | 1.46B | 865.41M | 832.27M | 753.92M | 352.94M | 309.32M | 331.56M | 309.39M | 312.26M | 368.91M | 237.43M | 253.99M |
| Property, Plant & Equipment | 3.40M | 3.44M | 3.57M | 3.47M | 3.63M | 3.62M | 15.13M | 15.09M | 14.97M | 15.13M | 15.61M | 16.18M |
| Goodwill | 101.54M | 101.54M | 101.54M | 101.54M | 101.54M | 101.54M | 105.25M | 105.25M | 105.25M | 105.25M | 103.37M | 103.77M |
| Intangible Assets | 209.24M | 217.34M | 225.44M | 233.53M | 250.13M | 258.39M | 266.65M | 274.90M | 283.16M | 291.42M | 299.61M | 314.84M |
| Total Assets | 2.19B | 1.53B | 1.56B | 1.48B | 948.60M | 905.43M | 941.77M | 954.87M | 866.40M | 913.87M | 787.22M | 769.23M |
| Accounts Payable | 9.40M | 5.26M | 3.24M | 3.68M | 8.58M | 5.37M | 5.23M | 4.69M | 1.79M | 1.89M | 2.43M | 2.48M |
| Total Current Liabilities | 46.74M | 40.67M | 37.45M | 30.54M | 64.73M | 58.68M | 37.11M | 24.77M | 18.57M | 17.82M | 16.78M | 15.73M |
| Long-Term Debt | 1.13B | 446.90M | 446.19M | 445.49M | — | — | 0 | — | — | — | — | — |
| Total Liabilities | 1.22B | 534.78M | 543.42M | 526.60M | 120.08M | 109.90M | 111.33M | 113.69M | 91.21M | 107.35M | 86.30M | 101.33M |
| Shareholders' Equity | 967.52M | 997.32M | 1.02B | 950.17M | 827.31M | 795.59M | 830.44M | 841.18M | 775.20M | 806.52M | 700.91M | 667.90M |
| Retained Earnings | 583.25M | 594.74M | 608.09M | 578.22M | 461.38M | 456.53M | 498.98M | 530.07M | 537.24M | 589.15M | 503.02M | 484.83M |
| Total Debt | 1.13B | 446.90M | 446.19M | 445.49M | — | — | 0 | — | — | — | — | — |
| Net Cash (Debt) | 231.16M | 332.51M | 287.33M | 219.03M | 245.02M | 208.90M | 256.17M | 219.64M | 226.93M | 310.59M | 170.31M | 190.50M |
| Shares Outstanding | 19.92M | 20.03M | 19.77M | 19.66M | 19.41M | 19.28M | 19.11M | 18.76M | 18.10M | 17.92M | 17.56M | 17.42M |
This table shows 12 quarterly periods of Ligand Pharmaceuticals's balance sheet, from Q2 2026 back to Q3 2023, across 18 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow LGND's reporting calendar. What is a balance sheet?